AE	Adverse Events
ALB	Albumin
ALT	Alanine Aminotransferase
AST	Aspartate Aminotransferase
CapTem	Capecitabine and Temozolomide
CI	Confidence Interval
CR	Complete Response
CT	Computed Tomography
CTCAE	Common Terminology Criteria for Adverse Events
DCR	Disease Control Rate
ECOG PS	Eastern Cooperative Oncology Group Performance Status
GBq	Gigabecquerel
Gy	Gray
HCC	Hepatocellular Carcinoma
HPFS	Hepatic Progression-Free Survival
HR	Hazard Ratio
IQR	Interquartile Range
mRECIST	Modified Response Evaluation Criteria in Solid Tumors
NELM	Neuroendocrine Liver Metastases
NET	Neuroendocrine Tumor
NR	Not Reported/Not Reached
ORR	Objective Response Rate
OS	Overall Survival
PD	Progressive Disease
PFS	Progression-Free Survival
PET/CT	Positron Emission Tomography/CT
PR	Partial Response
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
ROBINS-I	Risk Of Bias In Non-randomized Studies of Interventions
SD	Stable Disease
SI	Symptom Improvement
SIRT	Selective Internal Radiation Therapy
SPECT/CT	Single-Photon Emission Computed Tomography/CT
SSA	Somatostatin Analog
SUVmax	Maximum Standardized Uptake Value
TACE	Transarterial Chemoembolization
TAE	Transarterial Embolization
TARE	Transarterial Radioembolization
WMO	Dutch Medical Research Involving Human Subjects Act
WHO	World Health Organization
Y-90	Yttrium-90